These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy. Levite M J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016 [TBL] [Abstract][Full Text] [Related]
10. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. Stansley BJ; Conn PJ Curr Opin Pharmacol; 2018 Feb; 38():31-36. PubMed ID: 29486374 [TBL] [Abstract][Full Text] [Related]
12. Developmental expression of mGlu2 and mGlu3 in the mouse brain. McOmish CE; Demireva EY; Gingrich JA Gene Expr Patterns; 2016 Nov; 22(2):46-53. PubMed ID: 27818290 [TBL] [Abstract][Full Text] [Related]
13. Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 - present). Qunies AM; Emmitte KA Expert Opin Ther Pat; 2021 Aug; 31(8):687-708. PubMed ID: 33719801 [TBL] [Abstract][Full Text] [Related]
14. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders. Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693 [TBL] [Abstract][Full Text] [Related]
15. A group II metabotropic glutamate receptor 3 (mGlu3, GRM3) isoform implicated in schizophrenia interacts with canonical mGlu3 and reduces ligand binding. García-Bea A; Bermudez I; Harrison PJ; Lane TA J Psychopharmacol; 2017 Dec; 31(12):1519-1526. PubMed ID: 28655286 [TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction. Walker AG; Wenthur CJ; Xiang Z; Rook JM; Emmitte KA; Niswender CM; Lindsley CW; Conn PJ Proc Natl Acad Sci U S A; 2015 Jan; 112(4):1196-201. PubMed ID: 25583490 [TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate receptors in the control of mood disorders. Witkin JM; Marek GJ; Johnson BG; Schoepp DD CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147 [TBL] [Abstract][Full Text] [Related]
19. Metabotropic glutamate receptor 3 (mGlu3; mGluR3; GRM3) in schizophrenia: Antibody characterisation and a semi-quantitative western blot study. García-Bea A; Walker MA; Hyde TM; Kleinman JE; Harrison PJ; Lane TA Schizophr Res; 2016 Nov; 177(1-3):18-27. PubMed ID: 27130562 [TBL] [Abstract][Full Text] [Related]
20. Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Wierońska JM; Pilc A Neurochem Int; 2009; 55(1-3):85-97. PubMed ID: 19428811 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]